Article Information
vol. 3 no. 108 108ps44
- .
Author Information
- Sjoerd H. van der Burg1,*,†,
- Michael Kalos2,*,
- Cécile Gouttefangeas3,
- Sylvia Janetzki4,
- Christian Ottensmeier5,
- Marij J. P. Welters1,
- Pedro Romero6,
- Cedrik M. Britten7,8 and
- Axel Hoos9,†
- 1Department of Clinical Oncology, Leiden University Medical Center, Leiden, Netherlands.
- 2Translational and Correlative Studies Laboratory, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
- 3Institute for Cell Biology, Department of Immunology, Eberhard Karls University, D-72076 Tuebingen, Germany.
- 4ZellNet Consulting, Inc., Fort Lee, NJ 07024, USA.
- 5Experimental Cancer Medicine Center, University of Southampton, Southampton SO16 6YD, UK.
- 6Ludwig Center for Cancer Research of the University of Lausanne, CH-1011 Lausanne, Switzerland.
- 7Medical Department, Johannes Gutenberg University, Mainz, Germany.
- 8Ribological GmbH, 55101 Mainz, Germany.
- 9Bristol-Myers Squibb, Global Clinical Research, Oncology, Wallingford, CT 06492, USA.
- *These authors have contributed equally to this work.
- ↵†Corresponding authors: axel.hoos{at}bms.com (A.H.); shvdburg{at}lumc.nl (S.H.v.d.B.)